Foamix Pharmaceuticals Ltd (FOMX)

[tdeck]

DD on Executives/Directors and what they bring.

Foamix has a wealth of knowledge and experience, I see people many times in stocks/companies say oh that's like this, this will do this because that one did, etc. That is a rather naive way of looking at anything cynical almost, caution is one thing cynicism or the feeling one knows everything is just downright naive.

Lets just start at the top the CEO and a little about him and what he brings to the table and why he might be the one that was chosen.
Including a number things I found said/written about him through other sources that the Fomix website management page.

CEO David Domzalski was the Vice President, of Sales and Marketing, at LEO Pharma, Warner Chilcott and a SVP and General Manager at Azur Pharma, before Azur and Jazz Pharma merged in 2011 forming Jazz Pharmaceuticals PLC. Azur Pharma was a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia.

Mr. Domzalski has extensive experience in building and restructuring commercial organizations, launching successful new products and managing multiple therapeutic drugs throughout their life-cycle. He has a history of specifically building sales forces and marketing strategies, and launching products that will be of direct value as Foamix commercializes AMZEEQ™.

Matt Wiley
Chief Commercial Officer

When the commercialization of AMZEEQ™ was a year out Foamix CEO brought in Mr. Wiley as he had previously worked with Mr. Wiley at Azure and subsequently Leo after their merge where Mr. While after 5 years with Azur went on to stay with the newly formed Jazz Pharmaceuticals for another 6 years before being plucked by the CEO and Foamix to lead the commercialization efforts for AMZEEQ™ and its sister product now in the approval stage FMX103. Prior to Azur he held roles in sales, marketing at Guilford/MGI Pharma, Salix, Cephalon and Rhone-Poulenc Rover.

Since joining Foamix in the lead up to approval for (FMX101) AMZEEQ™ Mr. Wiley created the development and execution of commercial strategies of the company’s product portfolio, including the planned launches of (FMX101) AMZEEQ™ for acute acne and FMX103 for rosacea.

Established sales team 4 major markets for US Launch, hired 4 top senior managers in major markets, 51 pharma reps, he established both trademark and patent protection and helped raise $70m in cash so that upon approval they could hit the ground running. Many companies upon receiving FDA approval have to build a sales force, develop a strategy raise cash etc. ALL this is already done, which is of utmost importance to shareholders especially the CASH issue, no dilution for cash raises, this has already been sorted.

From another investor more familiar with the pharma sales business is this which I add with thanks to him as I never would have even had a clue as to this issue and it already being sorted.

And discussion on Payers which is the hardest part of establishing strong front for sales, they already penetrated the market. According to CEO, they were given high praise from 3 KOL leaders in Dermatology.

In terms of payers, the company’s research revealed that most payers gave FMX101 a mean favor-ability score of 5 out of 7

Definition of Payers
https://www.prnewswire.com/news-releases/what-is-value-in-healthcare-the-payer-definition-300342246.html

Mutya Harsch
General Counsel and Chief Legal Officer

Now I am adding Ms. Harsch to this page as I think she was brought in not only for her legal background in Warner Chilcott another pharma but what also set her apart is that she was Special Counsel, Mergers & Acquisitions, at Cooley LLP. Not that it, but, it does happen that pharma firms like to buy other pharma firms once all the work is done and all the risk, possible failure which happens all to much in the pharma game and why drugs/medications/devices are so expensive when they first get introduced to the market.

The FDA approval process is the highest standard in the world and the costs associated for successes and failures add equally to the costs so pharma specifically will merge/acquire smaller companies with something as innovating and crucial as AMZEEQ™. Many complain about the cost of drugs etc, but, what is the alternative, not having them. Many also say, well the govt could fund the research, to that I say have you ever been to get a drivers license, enough said argument over. the government is a wasteful bloated bureaucracy where no one can be fired and there are 5 people to do one job, where all five are trying to avoid doing the job or getting one of the others to do the job.

But, anyway it is a possibility as with all pharma that a merger could happen, but, that is but one of a dozen things that could, but it is good the head counsel has played in that sandbox before as have the CEO and others at Foamix.

For the rest of the executives and directors, board members one can just say there is a wealth of knowledge and experience in the pharma game from the entire specter of big pharma and it is a well chosen team to execute the strategy ahead with AMZEEQ™ and FOMX103 in 8 months when its approval comes through and the continued trials and approvals ahead with FOMX102/104 1nd 105, which 105 just entered its phase 2 this past year and is expecting results of that trial in June, a very exciting year is ahead indeed with Foamix.